SELLAS Life Sciences Group Inc buy Maxi_Scalibusa
Start price
23.01.21
/
50%
€4.85
Target price
23.01.22
€50.00
Performance (%)
-9.65%
End price
24.01.22
€4.38
Summary
This prediction ended on 24.01.22 with a price of €4.38. With a performance of -9.65%, the BUY prediction for SELLAS Life Sciences Group Inc by Maxi_Scalibusa closed slightly in the red. Maxi_Scalibusa has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -21.359% | -21.359% | -13.830% | -82.766% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by Maxi_Scalibusa for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
In the thread Trading SELLAS Life Sciences Group Inc
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten